Answers are grounded in this paper and cite their sources.
This proof-of-concept feasibility study demonstrates that measures of time toxicity can be extracted through secondary analyses of RCTs. In CO.17, despite an overall OS benefit with cetuximab, home days were statistically similar across arms. Such data can supplement traditional survival end points in RCTs. Further work should refine and validate the measure prospectively.[Media: see text].
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: